单源双螺旋四维双能CT用于胸部区域质子治疗计划制定的临床可行性
本研究对3例肺癌患者行双螺旋四维双能CT扫描,评估图像配准、质子剂量计算及基于双能CT的阻停比预测。结果显示经可变形图像配准后几何一致性高,临床计划在140 kVp与79 keV数据集上伽马通过率平均99.9%,基于双能CT的阻停比预测与临床启发式转换间平均射程偏移2.2%±1.2%。
要点
- 双螺旋四维双能CT未经配准时全患者体素平均NCC为98.7%±1.0%,仅肺为88.2%±7.8%。
- 可变形图像配准后全患者体素平均NCC达99.9%±0.1%,仅肺达99.6%±0.5%。
- 临床计划在140 kVp与79 keV数据集上伽马通过率平均99.9%(99.2%-100%)。
核心结论
- 79 keV伪单能CT数据集可从双螺旋四维双能CT稳定获得并适用于剂量计算。
- 基于双能CT的患者特异性阻停比预测表现良好,可能降低肺癌质子治疗的射程不确定性。
研究设计与样本
- 对3例肺癌患者采集双螺旋四维双能CT扫描。
- 评估时间平均数据集及4个呼吸时相下80 kVp与140 kVp扫描的几何一致性,以及后处理(含可变形图像配准)后58 keV与79 keV伪单能CT数据集的一致性。
- 在140 kVp与79 keV数据集上计算临床计划与针对膈肌的最差情况计划,行伽马分析(0.1%剂量差、1 mm距离一致性标准)。
- 研究基于双能CT的患者特异性阻停比预测的适用性,并与临床启发式CT值-阻停比转换比较质子射程偏移。
- 量化一名经验丰富的放射肿瘤科医生的勾画变异性。
主要发现
- 未经可变形图像配准的双螺旋四维双能CT扫描显示高几何一致性,全患者体素平均NCC±标准差为98.7%±1.0%,仅肺为88.2%±7.8%。
- 可变形图像配准改善一致性,全患者体素平均NCC为99.9%±0.1%,仅肺为99.6%±0.5%。
- 临床计划在140 kVp与79 keV数据集上剂量分布相似,平均伽马通过率99.9%(99.2%-100%)。
- 最差情况评估仍显示高通过率,平均99.3%,最低92.4%。
- 基于双能CT的患者特异性阻停比预测与临床启发式CT值-阻停比转换间平均射程偏移为2.2%±1.2%。
关键数值与推荐
- 几何一致性以归一化互相关(NCC)评估。
- 剂量计算比较采用伽马分析,标准为0.1%剂量差与1 mm距离一致性。
- 临床计划伽马通过率平均99.9%(99.2%-100%),最差情况计划平均99.3%(最低92.4%)。
- 基于双能CT的阻停比预测与临床启发式转换间平均射程偏移2.2%±1.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Single-source dual-spiral dual-energy computed tomography (DECT) provides additional patient information but is prone to motion between the 2 consecutively acquired computed tomography (CT) scans. Here, the clinical applicability of dual-spiral time-resolved DECT (4D-DECT) for proton treatment planning within the thoracic region was evaluated. METHODS AND MATERIALS: Dual-spiral 4D-DECT scans of 3 patients with lung cancer were acquired. For time-averaged datasets and 4 breathing phases, the geometric conformity of 80 kVp and 140 kVp 4D-DECT scans before image post-processing was assessed by normalized cross correlation (NCC). Additionally, the conformity of the corresponding DECT-derived 58 keV and 79 keV pseudo-monoenergetic CT datasets after image post-processing, including deformable image registration (DIR), was determined. To analyze the reliability of proton dose calculation, clinical (PlanClin) and artificial worst-case (PlanWorstCase, targeting the diaphragm) treatment plans were calculated on 140 kVp and 79 keV datasets and compared with gamma analyses (0.1% dose-difference and 1 mm distance-to-agreement criterion). The applicability of a patient-specific DECT-based prediction of stopping-power ratio (SPR) was investigated and proton range shifts compared with the clinical heuristic CT-number-to-SPR conversion were assessed. Finally, the delineation variability of an experienced radiation oncologist was quantified. RESULTS: Dual-spiral 4D-DECT scans without DIR showed a high geometric conformity, with an average NCC ± standard deviation of 98.7% ± 1.0% when including all patient voxels or 88.2% ± 7.8% when considering only lung. DIR improved the conformity, leading to an average NCC of 99.9% ± 0.1% and 99.6% ± 0.5%, respectively. PlanClin dose distributions on 140 kVp and 79 keV datasets were similar, with an average gamma passing rate of 99.9% (99.2%-100%). The worst-case evaluation still revealed high passing rates (99.3% on average, 92.4% as minimum). Clinically relevant mean range shifts of 2.2% ± 1.2% were determined between patient-specific DECT-based SPR prediction and clinical heuristic CT-number-to-SPR conversion. The intra-observer delineation variability was slightly reduced using additional DECT-derived datasets. CONCLUSIONS: The 79 keV pseudo-monoenergetic CT datasets can be consistently obtained from dual-spiral 4D-DECT and are applicable for dose calculation. Patient-specific DECT-based SPR prediction performed well and potentially reduces range uncertainty in proton therapy of patients with lung cancer.
引用
- Wohlfahrt P, Troost EGC, Hofmann C, et al. Clinical Feasibility of Single-Source Dual-spiral 4D Dual-Energy CT for Proton Treatment Planning Within the Thoracic Region. Int J Radiat Oncol Biol Phys. 2018. PMID: 30003998. doi:10.1016/j.ijrobp.2018.06.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。